If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Allergic Rhinitis and Airway Reactivity to Mediators

$39.50 plus tax (Refund Policy)

Buy Article:


Why some members of the family develop allergic rhinitis and others develop asthma has puzzled allergists for many years. We have reviewed our experience with bronchoprovocation and airway reactivity to methacholine in subjects with allergic rhinitis, bronchial asthma and normal controls. All current asthmatics and only about 10% of normal subjects with a negative family history for atopy respond to methacholine after 200 breath units or less. Although about 50% of allergic rhinitis subjects may show >20% decrease in FEV1 with 800 breath units or less of methacholine, many of these subjects reach a "plateau" i.e. increasing the dose of methacholine does not result in a further decrease in FEV1. Only about 5% show a high positive response without a plateau phenomena. These subjects respond to 50 breath units or less, and the FEV1 shows a further decrease with increasing concentrations of methacholine. These subjects are at greater risk for developing bronchial asthma.

Document Type: Research Article

DOI: http://dx.doi.org/10.2500/108854182779089256

Publication date: September 1, 1982

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • ingentaconnect is not responsible for the content or availability of external websites
Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more